On Monday, BTIG adjusted its stance on AnaptysBio (NASDAQ: NASDAQ:ANAB) shares, moving its rating from Buy to Neutral. The shift comes as the biotechnology company, currently valued at $759.5 million, braces for topline data from its Phase 2b trial of ANB032 in atopic dermatitis, expected later in December.
According to InvestingPro data, the company has shown strong momentum with a 66.4% return over the past year, though analysts don't expect profitability this year. The trial's outcome is seen as high risk/high reward due to the novel clinical approach for the drug class and the absence of prior clinical data.
ANB032, a BTLA agonist, is being evaluated for its efficacy in treating atopic dermatitis, a condition commonly driven by Th2 cytokines. The drug is considered to be potentially less potent as a Th2 inhibitor compared to existing treatments such as Dupixent by Sanofi/Regeneron and Egblyss by Eli Lilly (NYSE:LLY), neither of which are rated by BTIG.
Despite this, AnaptysBio's management maintains that similar efficacy and safety to Dupixent could justify further development due to ANB032's differentiated mechanism of action (MOA).
The Phase 2b trial is particularly focused on biologic-naïve patients, with the company aiming for at least a 40% absolute EASI-75 response rate. Moreover, the trial includes a subset of patients who have previously used Dupixent, representing about 15% of participants.
InvestingPro analysis reveals the company maintains a strong financial position with liquid assets exceeding short-term obligations and operates with moderate debt levels, providing stability during this crucial trial phase. BTIG is keen on observing any signs of durable efficacy within this group, even though the trial isn't fully designed to assess ANB032's performance in this segment with high unmet medical needs.
The recent discontinuation of Eli Lilly's peresolimab for rheumatoid arthritis in October 2024 has cast a shadow on the sector, suggesting potential significant downside risk for AnaptysBio's shares if the Phase 2b trial results are unfavorable. With a beta of -0.24, the stock typically moves opposite to market trends, which could provide some portfolio diversification benefits.
InvestingPro subscribers have access to 12 additional investment tips and comprehensive financial metrics to better assess the risk-reward profile of this biotechnology investment. Adverse outcomes, such as a placebo-corrected EASI-75 below 35% or serious safety concerns, could notably impact the company's stock value, possibly driving it below its fourth-quarter 2024 estimated cash value of approximately $14 per share.
The analyst's summary of expectations for the trial's EASI-75 outcomes aims to provide clarity on what the results may imply for AnaptysBio's shares.
In other recent news, AnaptysBio has been the focus of various financial firms' analysis. Truist Securities maintained their hold rating on AnaptysBio with a price target of $30, following the company's presentation at the American College of Rheumatology.
The firm highlighted AnaptysBio's research into the role of PD-1 in Rheumatoid Arthritis, as part of the broader effort to develop effective treatments for the autoimmune disease.
Guggenheim reiterated its Buy rating, expressing confidence in the company's BTLA agonist, ANB032, in treating autoimmune diseases. The firm foresees more than fourfold upside potential from the upcoming trial results. Leerink Partners trimmed their target price but maintained an Outperform rating due to AnaptysBio's robust portfolio.
AnaptysBio reported a third-quarter net loss of $32.9 million, with a significant increase in collaboration revenue, rising to $30 million. H.C. Wainwright reduced its price target for AnaptysBio due to an increase in operating expenses and a third-quarter operating loss of $22.8 million.
The company's ANB032 is advancing to a Phase 2b ARISE-AD trial, and rosnilimab is proceeding to a Phase 2b RENOIR RA trial. Positive results have also been reported from the GEMINI-1 and GEMINI-2 Phase 3 trials for imsidolimab, a treatment for generalized pustular psoriasis. These are the recent developments in AnaptysBio's financial and clinical progress.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.